$0.85 EPS Expected for DexCom, Inc. (NASDAQ:DXCM) This Quarter

Equities research analysts expect that DexCom, Inc. (NASDAQ:DXCM) will announce $0.85 earnings per share (EPS) for the current quarter, according to Zacks. Eight analysts have made estimates for DexCom’s earnings, with the lowest EPS estimate coming in at $0.71 and the highest estimate coming in at $0.93. DexCom posted earnings per share of $0.91 during the same quarter last year, which would indicate a negative year-over-year growth rate of 6.6%. The business is scheduled to issue its next earnings results on Thursday, February 10th.

On average, analysts expect that DexCom will report full year earnings of $2.79 per share for the current year, with EPS estimates ranging from $2.43 to $2.91. For the next financial year, analysts expect that the firm will post earnings of $3.45 per share, with EPS estimates ranging from $2.56 to $4.08. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for DexCom.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 28th. The medical device company reported $0.89 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.27. The company had revenue of $650.20 million during the quarter, compared to analyst estimates of $617.07 million. DexCom had a return on equity of 14.65% and a net margin of 22.82%. The firm’s quarterly revenue was up 29.8% compared to the same quarter last year. During the same period last year, the company posted $0.94 earnings per share.

A number of research analysts have recently weighed in on the company. Piper Sandler raised their target price on DexCom from $650.00 to $675.00 and gave the company an “overweight” rating in a report on Friday, October 29th. Stephens increased their price target on DexCom from $468.00 to $546.00 and gave the stock an “overweight” rating in a research note on Friday, July 30th. Wells Fargo & Company lifted their price target on shares of DexCom from $380.00 to $475.00 and gave the stock an “equal weight” rating in a report on Friday, July 30th. Citigroup upped their price objective on shares of DexCom from $630.00 to $660.00 and gave the company a “buy” rating in a research note on Friday, October 29th. Finally, SVB Leerink increased their target price on shares of DexCom from $500.00 to $715.00 and gave the stock an “outperform” rating in a report on Friday, October 29th. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $574.44.

In other news, EVP Chad Patterson sold 141 shares of the firm’s stock in a transaction dated Wednesday, October 13th. The stock was sold at an average price of $545.54, for a total transaction of $76,921.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Steven Robert Pacelli sold 6,743 shares of DexCom stock in a transaction dated Thursday, September 23rd. The stock was sold at an average price of $573.34, for a total value of $3,866,031.62. The disclosure for this sale can be found here. Insiders sold a total of 38,862 shares of company stock worth $21,958,010 in the last 90 days. 0.52% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jefferies Group LLC lifted its stake in DexCom by 7.0% in the second quarter. Jefferies Group LLC now owns 10,700 shares of the medical device company’s stock worth $4,569,000 after purchasing an additional 700 shares during the last quarter. Tiedemann Advisors LLC bought a new stake in DexCom in the second quarter worth about $1,377,000. Oppenheimer & Co. Inc. lifted its stake in DexCom by 7.4% in the second quarter. Oppenheimer & Co. Inc. now owns 10,341 shares of the medical device company’s stock worth $4,416,000 after purchasing an additional 712 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in DexCom by 42.1% in the second quarter. Nuveen Asset Management LLC now owns 1,830,424 shares of the medical device company’s stock worth $781,591,000 after purchasing an additional 542,070 shares during the last quarter. Finally, Blair William & Co. IL raised its stake in shares of DexCom by 1.7% during the second quarter. Blair William & Co. IL now owns 1,206,782 shares of the medical device company’s stock valued at $515,296,000 after acquiring an additional 20,119 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

NASDAQ DXCM traded up $8.58 on Thursday, reaching $598.58. The stock had a trading volume of 729,061 shares, compared to its average volume of 720,204. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.98 and a quick ratio of 4.50. DexCom has a 1-year low of $311.01 and a 1-year high of $659.45. The company has a market cap of $58.02 billion, a P/E ratio of 114.45 and a beta of 0.73. The firm has a fifty day moving average of $582.00 and a two-hundred day moving average of $494.32.

About DexCom

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

Featured Story: Blue-Chip Stocks

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.